Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis

Journal of Rheumatology

Volumn 30, Issue 6, 2003, Pages 1341-1343

  Clowse, Megan E B ^a   Wigley, Fredrick M ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Antineoplastic Agents Carboplatin; Gemcitabine; Necrosis; Scleroderma

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CALCIUM CHANNEL BLOCKING AGENT; CARBOPLATIN; CEFALEXIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FLUOXYMESTERONE; GABAPENTIN; GEMCITABINE; GINKGO BILOBA EXTRACT; ITRACONAZOLE; METHOTREXATE; MULTIVITAMIN; PREDNISONE; TAMOXIFEN; THIOTEPA; VINBLASTINE; VINCRISTINE;

ADULT; AMPUTATION; ARTERY THROMBOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIGITAL NECROSIS; FEMALE; FOLLOW UP; GRAPE; HISTOPLASMOSIS; HUMAN; HUMAN TISSUE; LUNG CANCER; NECROSIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RISK FACTOR; SCLERODERMA; SYSTEMIC SCLEROSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; VEIN OCCLUSION; VEIN THROMBOSIS;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; FINGERS; GANGRENE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFARCTION; MIDDLE AGED; NECROSIS; SCLERODERMA, SYSTEMIC;

EID: 0037642517     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
2. LeRoy EC. Systemic sclerosis: A vascular perspective. Rheum Dis Clin North Am 1996;22:675-94.
3. Wigley FM, Wise RA, Miller R, Needleman BW, Spence RJ. Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis Rheum 1992;35:688-93.
4. Marie I, Levesque H, Plissonnier D, Balguerie X, Cailleux N, Courtois H. Digital necrosis related to cisplatin in systemic sclerosis. Br J Dermatol 2000;142:833-4.
5. Kalapura T, Krishnamurthy M, Reddy CV. Acute myocardial infarction following gemcitabine therapy: a case report. Angiology 1999;50:1021-5.
6. Dobbie M, Hofer S, Oberholzer M, Herrmann R. Veno-occlusive disease of the liver induced by gemcitabine. Ann Oncol 1998;9:681.
7. Elomaa I, Pajunen M, Virkkunen P. Raynaud's phenomenon progressing to gangrene after vincristine and bleomycin therapy. Acta Med Scand 1984;216:323-6.
8. Yano S, Shimada K. Vasospastic angina after chemotherapy with carboplatin and etoposide in a patient with lung cancer. Jpn Circ J 1996;60:185-8.
9. Flombaum CD, Mouradian JA, Casper ES, Erlandson RA, Benedetti F. Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine. Am J Kidney Dis 1999;33:555-62.
10. Doll DC, List AF, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intem Med 1986;105:48-51.
11. Barcelo R, Lopez-Vivanco G, Mane JM, Rubio I, Munoz A, Fernandez R. Distal ischemic changes related to combination chemotherapy with cisplatin and gemcitabine: description of four cases. Ann Oncol 2000;11:1191-4.
12. Dumontet C, Morschhauser F, Solal-Celigny P, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol 2001; 113:772-8.
13. Wall JG, Weiss RB, Norton L, et al. Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: a Cancer and Leukemia Group B Study. Am J Med 1989;87:501-4.
14. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286-94.
15. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404-7.
16. Nicolson GL, Custead SE. Effects of chemotherapeutic drugs on platelet and metastatic tumor cell-endothelial cell interactions as a model for assessing vascular endothelial integrity. Cancer Res 1985;45:331-6.
17. Feffer SE, Carmosino LS, Fox RL. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer 1989;63:1303-7.
18. Canobbio L, Fassio T, Ardizzoni A, et al. Hypercoagulable state induced by cytostatic drugs in stage II breast cancer patients. Cancer 1986;58:1032-6.